30-04-2025
Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
BOSTON--(BUSINESS WIRE)--Apr 30, 2025--
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, May 7 th at 12:00 p.m. ET at the New York Hilton Midtown.
A live webcast of Ironwood's fireside chat will be accessible through the Investors section of the company's website at A replay of the webcast will be available on Ironwood's website following the conference.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (Nasdaq: IRWD) is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases. Ironwood is advancing apraglutide, a next-generation, long-acting synthetic GLP-2 analog being developed for short bowel syndrome patients who are dependent on parenteral support. In addition, Ironwood has been a pioneer in the development of LINZESS ® (linaclotide), the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). LINZESS is also approved for the treatment of functional constipation in pediatric patients ages 6-17 years old. Building upon our history of innovation, we keep patients at the heart of our R&D and commercialization efforts to reduce the burden of diseases and address significant unmet needs.
Founded in 1998, Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts, with a site in Basel, Switzerland.
We routinely post information that may be important to investors on our website at In addition, follow us on X and on LinkedIn.
View source version on
CONTACT: Company contact:
Greg Martini
[email protected]:
Precision AQ (formerly Stern Investor Relations)
Stephanie Ascher
[email protected]
KEYWORD: UNITED STATES NORTH AMERICA NEW YORK MASSACHUSETTS
INDUSTRY KEYWORD: HEALTH MANAGED CARE RESEARCH PHARMACEUTICAL SCIENCE BIOTECHNOLOGY
SOURCE: Ironwood Pharmaceuticals, Inc.
Copyright Business Wire 2025.
PUB: 04/30/2025 04:25 PM/DISC: 04/30/2025 04:24 PM
